26.2 C

Talgentis Tablets Wins Premium Pharmaceutical Product of the Year Award

Benign prostatic hyperplasia (BPH) and erectile dysfunction drug, Talgentis wins pharmaceutical product of the year award

Talgentis Tablet has been honoured with the prestigious Premium Pharmaceutical Product of the Year award at the 8th Global Business Brands Summit & Awards. The event, held on Thursday, celebrated the efficacy and innovation behind Talgentis, recognising its impact on medical treatment.

Talgentis Tablets, a phosphodiesterase type 5 (PDE-5) inhibitor, is primarily used in the management of benign prostatic hyperplasia (BPH), erectile dysfunction (ED), and pulmonary hypertension (PH). The medication has gained acclaim for its effectiveness and the advanced technology employed in its development and production.

Kofikrom are brand owners and Marketing Authorization holders of Talgentis Tablets.

- Advertisement -

Dr. Kofi Addo-Agyekum, Chief Executive Officer and Founder of Kofikrom Pharmacy Ltd. expressed gratitude for the recognition, emphasizing that it serves as both an honour and a challenge to continue innovating in the pharmaceutical field. Dr. Addo-Agyekum hails from three generations of renowned pharmacists known for their sterling contribution to pharmaceutical service in Ghana.

Join our WhatsApp Channel for more news

Dr. Addo-Agyekum and his company have won several industry awards.

The Global Business Brands Summit & Awards, organized by the Entrepreneurs Foundation of Ghana, aims to acknowledge excellence and reward companies and brands for their outstanding performance and significant contributions to their industries and the economy.

- Advertisement -

The recognition of Talgentis Tablets underscores Kofikrom Pharmacy Ltd.’s commitment to advancing healthcare through innovative pharmaceutical solutions, setting a benchmark for quality and efficacy in the industry.

While you're here, we just want to remind you of our commitment to telling the stories that matter the most.Our commitment is to our readers first before anything else.

Our Picks



Get the Stories Right in Your Inbox